THERAPY DOSSIER · th-ccbfb04c8474

Allogeneic embryonic day 13.5 foetal lung tissue

Biologic · Transplantation of intact allogeneic embryonic-stage lung tissue at the pseudoglandular stage, intended to act as an organ-committed progenitor graft that expands and differentiates in the recipient. Not a chemical entity; no ChEMBL record is possible.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Transplantation of intact allogeneic embryonic-stage lung tissue at the pseudoglandular stage, intended to act as an organ-committed progenitor graft that expands and differentiates in the recipient. Not a chemical entity; no ChEMBL record is possible.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32259837 ↗2020Reported benefit

Orthotopic foetal lung tissue direct injection into lung showed a preventive effect against paraquat-induced acute lung injury in mice.

MouseChemical/toxinC57BL/6 (green fluorescent protein donors)Direct orthotopic injection into the left lungImplantation before paraquat challenge (preventive design)

Model: Paraquat-induced severe acute lung injury

Survival was 39 percent in the foetal lung implantation group versus 5.9 percent in the vehicle group (p=0.034), with reduced inflammatory cells and oedema, increased proliferation of implanted foetal lung cells and significantly less airway septal thickening (p<0.001).

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…